Axsome Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AXSM Nasdaq 2830 www.axsome.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Axsome Therapeutics, Inc.

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone - May 13th, 2025 11:00 am
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years - May 12th, 2025 11:08 am
3 Monster Stocks in the Making - May 11th, 2025 3:15 pm
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter Results - May 8th, 2025 10:22 am
Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... - May 6th, 2025 7:02 am
Q1 2025 Axsome Therapeutics Inc Earnings Call - May 6th, 2025 4:24 am
The three-year returns have been enviable for Axsome Therapeutics (NASDAQ:AXSM) shareholders despite underlying losses increasing - May 5th, 2025 1:12 pm
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - May 5th, 2025 11:00 am
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month - May 1st, 2025 11:00 am
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline - Apr 28th, 2025 2:00 pm
Axsome Therapeutics to Participate in Upcoming Investor Conferences - Apr 22nd, 2025 11:00 am
Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy - Apr 10th, 2025 10:18 am
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 - Apr 8th, 2025 11:00 am
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting - Apr 4th, 2025 11:00 am
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week - Apr 1st, 2025 8:04 pm
Why Shares of Axsome Therapeutics Slumped Today - Apr 1st, 2025 5:23 pm
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) - Apr 1st, 2025 11:00 am
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. - Mar 25th, 2025 4:53 pm
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - Mar 25th, 2025 11:00 am
Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? - Mar 20th, 2025 3:30 pm